Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study by Setiawati, Arini et al.
223
ORIGINAL ARTICLE
Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine
Clinical Effectiveness, Safety and Tolerability  
of Amlodipine/Valsartan in Hypertensive Patients:  
the Indonesian Subset of the EXCITE Study
Arini Setiawati1,2, Harmani Kalim3, Arif Abdillah4
1 Clinical Study Unit, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
2 Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia 
3 Jenderal Ahmad Yani Road, No: I/C-13, East Jakarta, Indonesia 
4 PT. Novartis Indonesia, Jakarta, Indonesia.
Correspondence mail:
Clinical Study Unit, Faculty of Medicine Universitas Indonesia. Jl. Salemba 6 Jakarta 10430, Indonesia. 
email: arinisetiawati@yahoo.com.
ABSTRAK 
Tujuan: menilai keefektifan, keamanan dan tolerabilitas kombinasi tetap amlodipine/valsartan (Aml/Val) 
pada pasien hipertensi dalam praktek klinik sehari-hari. Metode: subset Indonesia dari studi EXCITE (clinical 
EXperienCe of amlodIpine and valsarTan in hypertEnsion), yang merupakan studi terbuka, observasional, 
prospektif dan multinasional pada pasien hipertensi yang diobati dengan kombinasi tetap Aml/Val selama 
26 minggu. Kombinasi tetap Aml/Val 5/80, 5/160 atau 10/160 mg diberikan sebagai obat monoterapi atau 
ditambahkan pada obat antihipertensi lain pada pasien yang tidak terkontrol oleh monoterapi sebelumnya. 
Outcome keefektifan yang diukur adalah (1) rata-rata penurunan TDS (tekanan darah sistolik) dan TDD 
(tekanan darah diastolik) duduk dari awal terapi ke minggu 26; (2) proporsi pasien yang mencapai kontrol TD 
(<140/90 mmHg pada pasien bukan diabetes atau <130/80 mmHg pada pasien diabetes); (3) proporsi pasien 
yang merupakan responder (mencapai kontrol TD atau penurunan TD >20/10 mmHg). Outcome keamanan 
yang diukur adalah insidens kejadian tidak diinginkan (KTD) dan KTD serius (KTDS), dan insidens edema. 
Hasil: total 500 pasien dari Indonesia mendapat kombinasi tetap Aml/Val, 487 pasien dianalisis untuk efikasi, 
dan 464 pasien menyelesaikan studi. Pada akhir studi (minggu 26), rata-rata penurunan TDS dan TDD 
duduk (95% CI) dari awal terapi adalah -33,7 (-35,2 g -32,1) mmHg dan -14,8 (-15,7 g -13,8) mmHg. Di 
antara 487 pasien ini, 52,4% pasien mencapai kontrol TD dan 80,5% pasien adalah responder (LOCF). Di 
antara 464 pasien yang menyelesaikan studi, 53,7% pasien mencapai kontrol TD dan 84,5% pasien adalah 
responder. Kombinasi tetap Aml/Val efektif dalam menurunkan TD pada pasien Indonesia. Total pasien dengan 
KTD, termasuk KTDS, adalah 11,4%, 1% dengan KTDS, dan 0,8% pasien meninggal. KTDS dan kematian 
diperkirakan tidak berhubungan dengan obat studi. Edema dilaporkan oleh 9,4% pasien pada awal studi dan 
3,7% pada akhir studi. Peneliti menilai bahwa keefektifan obat, serta tolerabilitas dan kepatuhan pasien, baik 
dan sangat baik pada 90,8%, 92,2% dan 89,2% pasien berturut-turut. Kesimpulan: kombinasi tetap Aml/Val 
efektif dan ditoleransi dengan baik untuk menurunkan TD pada pasien hipertensi, yang tidak terkontrol dengan 
monoterapi, dalam praktek sehari-hari di Indonesia.
ABSTRACT
Aim: to assess the effectiveness, safety and tolerability of amlodipine/valsartan (Aml/Val) single-pill 
combination (SPC) in hypertensive patients in a real-world setting. Methods: the Indonesian subset of the 
EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, 
prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks. Aml/Val 
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SPCs (5/80, 5/160, 10/160 mg) were administered as monotherapy or as add-on therapy to other antihypertensive 
medications in patients not controlled by prior monotherapy. The effectiveness outcomes were (1) mean decrease 
in sitting systolic blood pressure and diastolic blood pressure (msSBP and msDBP) from baseline to week 26; (2) 
proportion of patients achieving BP goal (<140/90 mmHg for nondiabetics, or <130/80 mmHg for diabetics); (3) 
proportion of patients who were responders (achieving BP goal or BP reduction of >20/10 mmHg). The safety 
variables were the incidence of AEs and SAEs, and the incidence of edema. Results: a total of 500 patients from 
Indonesia received Aml/Val SPC, 487 patients were analyzed for efficacy (by LOCF), and 464 patients completed 
the study. At study end (week 26), the overall msSBP and msDBP(95% CI) reductions from baseline were -33.7 
(-35.2, -32.1) mmHg and -14.8 (-15.7, -13.8) mmHg, respectively. Among the 487 patients, 52.4% achieved 
BP goal and 80.5% were responders (LOCF). Among 464 patients who completed the study, 53.7% achieved 
BP goal and 84.5% were responders. Aml/Val SPC was effective in decreasing BP in Indonesian patients. AEs, 
including SAEs, were reported in 11.4% patients, with SAEs in 1% of patients, and death in 0.8% of patients. 
SAEs and deaths were considered unrelated to the study drug. Edema was reported by 9.4% of patients at 
baseline, and in 3.7% patients at end of study. Effectiveness, tolerability and compliance were rated good and 
very good in 90.8%, 92.2%, and 89.2% of patients, respectively, according to the investigators. Conclusion: Aml/
Val SPC was effective for BP reductions and well tolerated in hypertensive patients, not adequately controlled 
by monotherapy, in a daily clinical setting in Indonesia.
Key words: Aml/Val, single-pill combination, daily clinical, EXCITE study.
INTRODUCTION
Hypertension is a common medical problem 
in developing countries, and rates of awareness, 
treatment, and control are generally low. More 
than 80% of the world population lives in 
developing countries, where most of the world 
burden of hypertension exists. By 2025, almost 
three-quarters of people with hypertension 
will be living in developing countries.1 High 
illiteracy rates, poor access to health facilities, 
bad dietary habits, poverty, and high cost of 
drugs contribute to poor blood pressure control 
in these countries.2
The prevalence of hypertension among 
Indonesian adults (≥18 years) is 26.5-31.7%.3,4 
Those who are aware that they have the disease 
are 7.7-9.5%3,4 and 2.3% take antihypertensive 
medication.4
Until now, there were only 4 published 
papers on antihypertensive treatments in 
Indonesia, one study was a bridging study 
of labetalol for hypertension in Indonesia5, 2 
studies were randomized clinical trials6,7, and 
another study was a postmarketing observational 
study of candesartan and candesartan/HCT.8 
According to the clinical trials, achievement of 
BP control varied from 26.9% to 45%5-7, while 
the postmarketing study showed BP control of 
53% in patients, not adequately controlled by 
previous therapy.8
International guidelines recommend that 
most patients with hypertension will require 
more than one antihypertensive medication 
to achieve their BP goals. A combination of 
two drugs should be chosen from different 
classes, either as free or fixed combinations.9,10 
Combination of CCBs with ARBs are amongst 
the preferred ones.10 Single pill combinations 
(SPC) of amlodipine/valsartan (Aml/Val) has 
been shown to be highly effective and well 
tolerated in randomized clinical trials with 
Caucasians11-13,17, Asians14,15,17, and Blacks.16,17 
However, clinical trial setting is a restricted 
one and therefore does not reflect the real-world 
situation.
We were interested in knowing the 
performance of Aml/Val SPC in a real-world 
setting in Indonesia. Real-life studies of Aml/
Val combination have been conducted in many 
countries, including Asian and Middle-East 
countries, as multinational post-marketing 
studies (PMS).18-20 Indonesia was included in 
one of these PMSs, i.e. the EXCITE study20, 
although Indonesia has conducted its own study 
(the MAX-FORCE study).21 China status II22 
was another observational study conducted 
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in China that was not part of a multinational 
one, just as MAX-FORCE in Indonesia. As 
a subset of the EXCITE study, the primary 
objective of the present study was similar to 
that of the EXCITE study, i.e. to assess the 
effectiveness, safety and tolerability of Aml/
Val SPC therapies in hypertensive patients 
under routine clinical practice during 26 weeks 
of treatment. The secondary objectives were to 
evaluate patient adherence to treatment and the 
incidence of edema. Due to the limited data on 
antihypertensive treatments in Indonesia, this 
study would become an important addition to it.
METHODS
Male and female outpatients, aged ≥18 
years with essential hypertension not adequately 
controlled by previous antihypertensive 
medications, for whom treatment with SPC of 
Aml/Val was medically recommended as part of 
their medical care, were eligible for this study.
Patients with hypersensitivity to amlodipine, 
valsartan, or any of the excipients in the 
formulation, with severe renal impairment 
(creatinine clearance less than 10 ml/min) or 
severe hepatic impairment, with hereditary 
or history of angioedema, or any condition 
that according to the treating physicians 
prohibited participation in the study, were 
excluded. Pregnant women, nursing mothers, or 
women of child-bearing age without adequate 
contraception, were also excluded from this 
study.
Study Design and Procedure
The present study was the Indonesian subset 
of the EXCITE study. The EXCITE (clinical 
EXperienCe of amlodIpine and valsarTan 
in hypertEnsion) study was a multinational, 
multicenter, prospective, observational (non-
interventional), open (non-comparative) study 
in hypertensive patients treated with a SPC of 
Aml/Val for 26 weeks (4 routine examinations: 
at baseline, week 4, week 13, and week 26). No 
intervention beyond usual care was applied to 
the patients.
The protocol and informed consent were 
approved by an appropriate ethics committee. 
The study commenced in March 2011 and ended 
in September 2012. It was conducted in Jakarta, 
Surabaya, Malang, Bandung, Semarang, Bali, 
and Makassar.
As a postmarketing study, without control 
group, with the primary objective “effectiveness, 
safety and tolerability”, the sample size was 
determined without calculation (which is usually 
done for “efficacy” study), as many sample 
as possible were included but still affordable, 
usually between 500 and 1000 subjects. A total 
sample of 500 subjects were taken for this study.
Patient demographics and baseline 
characteristics were recorded at study entry, 
including: age, BMI, gender, race, ethnicity, 
duration of hypertension, risk factors, and other 
medical history including prior antihypertensive 
medications.
Aml/Val SPCs (5/80 mg, 5/160 mg, 10/160 
mg) were administered as monotherapy or 
as add-on therapy to other antihypertensive 
medications. The hypertension therapy at study 
entry was recorded in the CRF (case report 
form). Any changes to medication during study 
participation were recorded in the CRF.
Outcome Assessments
The main effectiveness outcomes were (1) 
change in mean sitting SBP and DBP (msSBP 
and msDBP) from baseline to week 26; (2) 
the proportion of patients achieving BP goal 
(<140/90 mmHg for non-diabetics, or <130/80 
mmHg for diabetics); (3) the proportion of 
patients who were responders (achieving BP goal 
or BP reduction of >20/10 mmHg).
Patients were requested to sit for at least 
5 minutes prior to BP measurement. BP was 
measured using mercury sphygmomanometer 
that has been calibrated. Korotkoff phase 1 and 
phase 5 were taken as SPB and DBP. BP was 
measured twice and the mean value was taken.
The safety variables were the incidence of 
adverse events (AEs) and serious adverse events 
(SAEs), and the incidence of edema.
Statistical Analysis
Effectiveness and safety analyses were 
performed using both FAS (Full Analysis 
Set) population (LOCF method) and PP (Per 
Protocol) population.
Data analyses were performed using 
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descriptive statistics for demographics and 
baseline characteristics, and for safety evaluation. 
For effectiveness, the decreases in BP from 
baseline to study end were analyzed using paired-t 
test (the decreases in BP should be normally 
distributed), and the 95% CIs (confidence 
intervals) of the BP decreases were calculated.
RESULTS
Patient Demographics and Baseline 
Characteristics
All 500 patients (from Indonesia) received 
Aml/Val SPC. Thirty five patients (7%) 
discontinued early, the most common reason was 
lost to follow-up (24 patients, 4.8%), followed by 
death (4 patients, 0.8%). Three patients (0.6%) 
discontinued because the study drug was no 
longer required, 2 patients (0.4%) due to adverse 
events and 2 patients (0.4%) withdrew consent. 
For one patient, demographic information 
was not collected. The remaining 464 patients 
(92.8%) completed the study (26 weeks).
Demographics and baseline characteristics 
of patients are shown in Table 1.
A l l  p a t i e n t s  r e c e i v e d  p r e v i o u s 
antihypertensive medications, which were 
primarily dihydropyridines (45.4%).
The most common reason for changing 
treatment was unsatisfactory BP control during 
prior treatment in 366 patients (73.2%), followed 
by insufficient compliance and insufficient 
tolerability with prior treatment in 141 patients 
(28.2%) and 86 patients (17.2%), respectively.
At baseline, concomitant antihypertensive 
medications were used in 46 patients (9.2%), 
1 drug in 39 patients (7.8%), and 2 drugs in 7 
patients (1.4%), mostly b-blockers in 22 patients 
(4.4%), followed by thiazides in 16 patients 
(3.2%). By end of study (week 26), 51 patients 
(10.2%) used concomitant antihypertensives, 
1 drug in 41 patients (8.2%), and 2 drugs in 
10 patients (2.0%), b-blockers were the most 
prevalent, used in 33 patients (6.6%), followed 
by thiazides in 7 patients (1.4%).
BP Reductions, Therapeutic Goal Attainment 
and Responders
By FAS (Full Analysis Set, N=487, because 
13 patients had only baseline BP), mean 
sitting blood pressure (msBP) decreased from 
164.1/96.4 mmHg at baseline to 130.5/81.6 
mmHg at week 26 (p<0.001) (Figure 1). The 
decreases in msSBP and msDBP (95% CI) were 
-33.7 (-35.2, -32.1) mmHg and -14.8 (-15.7, 
-13.8) mmHg, respectively (Figure 2). The 
therapeutic goal (BP <140/90 mmHg for non-
diabetics, or <130/80 mmHg for diabetics) was 
achieved by 255 patients (52.4%), and 80.5% 
were responders.
Table 1. Patient demographics and baseline characteristics
Variables Aml/Val  (N = 500)
Age (years), mean (SD) 55.8 (11.01)
Age >65 years, n (%) 102 (20.4)
Male, n (%) 273 (54.6)
Race, n (%)
 - Asia 489 (97.8)
 - Other 11 (2.2)
Ethnicity, n(%) 
 - Chinese 156 (31.2)
 - Other 344 (68.8)
BMI status (kg/m2), n (%)
 - <25 198(39.6)
 - 25 – 30 227 (45.4)
 - >30   65 (13.0)
 - missing 10 (2.0)
Duration of hypertention (yrs), mean 
(SD)
5.8 (6.72)
Cardiovascular risk factor, n (%)
 - None   94 (18.8)
 - Family history of HT 172 (34.4)
 - Dyslipidemia 213 (42.6)
 - Diabetes mellitus 138 (27.6)
 - Obesity 105 (21.0)
 - Smoking   60 (12.0)
 - Creatinine increase   30 (6.0)
 - Coronary heart disease 21 (4.2)
 - Myocardial infarction 6 (1.2)
 - Heart failure 4 (0.8)
Previous antihypertensive medications, 
n (%)
 - Dihydropyridines 227 (45.4)
 - ACE inhibitors 114(22.8)
 - ARBs 97(19.4)
 - b-blockers 32(6.4)
 - Thiazides 23 (4.6)
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The therapeutic goal independent of diabetic 
status (BP<140/90 mm Hg) was achieved by 306 
patients (62.8%).
Among the study completers (464 patients), 
msBP decreased from 164.3/96.4 mmHg at 
baseline to 130.3/81.5 mmHg at week 26, the 
decreases (95% CI) were -34.0 (-35.5, -32.4) 
mmHg and -14.9 (-15.85, -13.95) mmHg for 
msSBP and msDBP, respectively. The therapeutic 
goal was achieved by 249 patients (53.7%) and 
392 patients (84.5%) were responders.
By treatment dosage, the reductions in msSBP 
and msDBP from baseline to study end are shown 
in Figure 2. The therapeutic goal was achieved 
by 183 patients (54.8%), 55 patients (58.5%), and 
17 patients (29.3%) for dosages of 5/80, 5/160, 
and 10/160 mg, respectively.
Figure 3 shows mean BP reductions in 
subgroups of various baseline SBP after 26 
weeks of treatment. The higher the baseline SBP, 
the greater the reductions in msSBP and msDBP 
at end of study.
Mean sBP reductions at end of study in 
patients with ISH or elderly at baseline and in 
DM or obese patients are shown in Figure 4.
Safety and Tolerability
A total of 57 patients (11.4%) reported at 
least one adverse event, including 5 patients 
(1%) with serious adverse events. Excluding 
edema (Table 3), the most frequent adverse 
event was dyslipidemia in 13 patients (2.6%), 
followed by cough in 9 patients (1.8%), and 
headache in 7 patients (1.4%) (Table 2).
Figure 1. Mean sitting SBP and DBP during the study (last observation carried forward/LOCF) with Aml/Val SPC. Error bars 
represent SDs (standard deviations).
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Among 5 patients with SAEs, 4 died out 
of which, one patient experienced a non- 
hemorrhagic stroke on study day 118, and 3 
patients experienced myocardial infarction on 
study days 30, 92, and 140. None of these 4 
deaths were suspected to be related to the study 
drug. One other patient reported nonfatal SAEs 
(dyspnea, insomnia, edema), also not suspected 
to be related to the study drug.
At baseline, there were 47 patients 
(9.4%) with edema, among them, 28 had 
received dihydropyridines as the previous 
antihypertensives. At end of study (week 26), 
total patients with edema decreased to 17 (3.7%). 
Figure 3.  Mean sitting BP reductions at end of study (last observation carried forward/LOCF) in patients with various values 
of baseline SBP
Figure 4. Mean BP reductions at end of study (last observation carried forward/LOCF) in various subgroups of patients: isolated 
systolic hypertension (ISH), elderly, DM, and obese
Mean baseline
BP (mmHg)
140 - < 160
(n = 131)
147.5/91.7
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By treatment dosage, among 47 patients with 
edema at baseline, 36 patients received Aml/
Val 5/80 mg, 5 patients received Aml/Val 5/160 
mg, and 6 patients received Aml/Val 10/160 mg. 
At study end, among the remaining 17 patients 
with edema, there were 10 patients in the Aml/
Val 5/80 mg group, 2 patients in the Aml/Val 
5/160 mg group, and 5 patients in the Aml/Val 
10/160 mg group (Table 3).
Investigators’ Assessments
At the end of study, effectiveness, tolerability 
and compliance with treatment were assessed by 
the investigators (Table 4).
It was shown that effectiveness, tolerability, 
and compliance were rated good and very 
good in 90.8%, 92.2%, and 89.2% of patients, 
respectively, by the Investigators.
DISCUSSION
This was the Indonesian subset of the 
EXCITE study, which was a multinational, 
multicenter, prospective, postmarketing study in 
hypertensive patients treated with Aml/Val in a 
real-world setting. This study was very similar 
to a study conducted about one year earlier 
in Indonesia, the MAX-FORCE study.21 The 
complete EXCITE study included patients from 
Middle East countries as the majority, besides 
patients from Asian countries.20
The overall EXCITE study included about 
9800 patients, compared to the Indonesian subset 
study, it had more males (61 vs 55%), a little bit 
younger age (mean age 53 vs 56 years), and 94 
vs 93% completed the study.20 The premature 
discontinuation was also mainly due to lost to 
follow up (4 vs 7%).20 The MAX-FORCE study 
recruited 488 patients, with similar age and 
similar percentage of males with the present 
study, and also similar percentage of patients 
who completed the study (for only 12 weeks 
duration).21
The previous antihypertensive medications, 
in  the  present  s tudy  were  pr imar i ly 
dihydropyridines, followed by ACE inhibitors, 
ARBs, and b-blockers. The same order of 
previous antihypertensive medications was 
found in the overall EXCITE study and in the 
MAX-FORCE study.21
The decrease in mean BP in this subset of 
EXCITE study (last observation carried forward/
LOCF) was similar to the overall EXCITE 




Total patients with AEs, including 
SAEs
57 (11.4)
 - Dyslipidemia 13 (2.6)
 - Cough 9 (1.8)
 - Headache 7 (1.4)
 - Diabetes mellitus 4 (0.8) 
 - Gastritis 4 (0.8)
 - Rhinitis 4 (0.8) 
 - Hyperuricemia 3 (0.6) 
 - Myocardial infarction 3 (0.6)
 - Pharyngitis 3 (0.6)
 - Dyspepsia 2 (0.4)
 - Dyspnea 2 (0.4)
 - Inflammation 2 (0.4)
 - Myalgia 2 (0.4)
Note: one patient may experience more than one AE
Table 3. Edema by visit and treatment dosage: n (%)







Baseline 500 (100) 339 97 63
Total with 
edema
47 (9.4) 36 5 6
Mild 41 (8.2) 33 5 3
Moderate 4 (0.8) 2 - 2
Severe 2 (0.4) 1 - 1
End of 
study
464 (100) 321 92 50
Total with 
edema
17 (3.7) 10 2 5
Mild 14 (3.0) 8 1 5
Moderate 3 (0.6) 2 1 -
Severe - - - -
Table 4. Effectiveness, tolerability, and compliance with 
treatment at end of study: n (%)
Effectiveness Tolerability Compliance
Total 500 (100) 500 (100) 500 (100)
Good 306 (61.2) 306 (61.2) 286 (57.2)
Very good 148 (29.6) 155 (31.0) 160 (32.0)
Would continue Aml/Val 455 (91.0)
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study, i.e. -33.7/-14.8 vs -31.0/-16.6 mmHg. 
The percentage of patients achieving therapeutic 
goal (BP <140/90 mmHg for nondiabetics or 
<130/80 mmHg for diabetics) was also similar 
(52.4 vs 52.8%).
Recent guidelines for the management of 
hypertension23,24 mention that BP therapeutic 
goal for diabetics is <140/90 mm Hg. In this 
regard, the proportion of patients reaching 
therapeutic goal in the present study was 62.8%, 
which was comparable to the overall EXCITE 
study; 69.9%. In the MAX-FORCE study, the 
mean BP reductions from baseline to study 
end were -36.6/-16.4 mmHg, 62.4% achieved 
therapeutic goal (<140/90 mm Hg). These results 
showed that Aml/Val SPC has comparable 
efficacy in reducing BP in the present subset 
with the overall EXCITE study, and with the 
MAX-FORCE study as well.
The decrease in BP was proportional to 
the baseline: smallest decrease in the lowest 
baseline SBP, and greatest decrease in the highest 
baseline SBP (Figure 3). The same pattern of BP 
reduction was also shown in various grades of 
hypertensive patients (based on BP) in previous 
studies with Aml/Val SPC in real-world studies as 
well as in the main EXCITE study: the higher the 
grades of hypertension, the greater the decrease 
in BP.18-22 This is because the efficacy of CCBs 
in lowering BP is proportional to the baseline 
BP.25 This is also true for a combination of an 
ARB (irbesartan) and HCT.26 The magnitude of 
BP reductions by ARBs is less dependent on the 
baseline BP than it is by CCBs.27
For study completers (N = 464), 53.7% 
achieved therapeutic goal. In Pakistan subset 
study28, 471 patients (94%) received Aml/Val, 
and among the study completers (N=411), 
237 patients (57.7%) achieved therapeutic 
goal, comparable to our study. Results in 
previous real-life studies showed that BP control 
(<140/90mmHg) was achieved by 75.6% from 
a total of 2729 patients18, and by 77.7% from 
a total of 8336 patients19, after 12 weeks of 
treatment with Aml/Val.
Compared with the results of LOCF analysis, 
the study completers achieved slightly higher 
results: BP goal achieved by 52.4% vs 53.7%, 
responders 80.5% vs 84.5%. This is not 
unexpected because LOCF analysis includes 
early results which have lower values (the drug 
has not reached its maximal effects).
Aml/Val caused decrease in BP which was 
greater in patients receiving higher dosage: 
with the exception of 10/160 mg (Figure 2). 
This could be because the 5/160 mg and 10/160 
mg dosages were given to patients with higher 
grades of hypertension compared to patients 
receiving the 5/80 mg dosage.
For patients with ISH and the elderly, the 
decrease in BP followed the above pattern: the 
higher the baseline BP, the greater the decrease 
in BP and vice versa. It was shown very clearly 
in Figure 4, in ISH patients with very low DBP 
(<90 mmHg), Aml/Val produced very little 
decrease in DBP (mean -1.2 mmHg).
In the present study, the total number of 
patients with AEs, including SAEs was 11.4%, 
similar to the number found in the overall 
EXCITE study (11.2%).20 The most frequent AE 
was also the same, it was edema in this subset 
study (3.7%) and in the overall study it was 
edema and peripheral edema (2.0% and 1.2%).20 
In the other real-world studies of Aml/Val, the 
total number of patients with AEs ranged from 
1.4% to 8.8%18,19,21,22,28, and the most frequent 
AE was edema in 4 studies18,19,21,22 and nausea 
in 1 study.28
There were 5 patients (1%) with SAEs in 
the present subset study which were considered 
unrelated to the study drug. Forty nine patients 
(0.6%) in the overall EXCITE study20 had 
SAEs, the majority of these were considered 
unrelated to the study drug. In the other real-
world studies with Aml/Val, between 0 (zero) 
to 8 patients18,19,21,22,28 had SAEs, most of these 
SAEs were deemed not related to the study drug. 
There were 4 deaths in the present study, 
and 12 deaths in the overall EXCITE study20, 
none to 3 deaths in the other real-world studies 
of Aml/Val18,19,21,22,28, but all of the deaths were 
considered not related to the study drug.
Among the 47 patients with edema at 
baseline, 28 patients had dihydropyridines as the 
prior antihypertensive treatment, and therefore 
they were likely the cause of the edema. The 
edema subsided in 25 of the 28 patients during 
treatment with Aml/Val, persisted in 2 patients 
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and 1 patient was unevaluable (patient had 
only baseline visit). Edema caused by DHPs 
(vasodilation) could be counter balanced by the 
venodilatory action of the angiotensin receptor 
blocker (valsartan).29 The remaining 19 patients 
with edema at baseline did not receive previous 
CCBs, hence edema in these patients might 
be associated with the preexisting disease. 
The frequency of edema in the present study 
was 9.4% at baseline and 3.7% at study end. 
Compared to the other real-world studies of 
Aml/Val, in one study (N=2785)18, edema at 
baseline was 13.7% and 10.1% at end of study, 
in the other study (N=9090)19, edema at baseline 
was 10.4% and became 8.5% at study end, while 
in Pakistan subset study (N=471)28 edema was 
12.1% at baseline and 9.1% at study end. In 
the MAX-FORCE study (N=480)21, edema at 
baseline was 3.5% and 0.4% at end of study.
Effectiveness, tolerability, and compliance 
were rated good or very good in around 90% of 
patients, similar to the overall EXCITE20 and 
another real-life study18, and higher compared 
to Pakistan subset study (only around 70%).28
The present study was a postmarketing 
observational study and hence there were several 
limitations. First, as an open study, it has no 
control group, and non-blinded measurement 
of outcomes were performed. Second, as an 
observational study, it has no standardized 
methods for data collection. These factors 
may cause observer bias, which limits the 
interpretation of the results. It is difficult to 
draw definitive conclusions from the results of 
the study. 
However, an observational study from a 
real-life setting allows the inclusion of a wide 
variety of hypertensive patients, e.g. patients 
with different severities and different types of 
essential hypertension, patients with various 
concurrent diseases and concomitant medications. 
This heterogenous patient population with 
hypertension is more representative of the 
patient population encountered in routine 
clinical practice. It is encouraging that the BP 
reductions and the percentage of controlled BP 
in the present study are generally similar to the 
previous studies, whether in clinical trials11-17 
or in real-world setting.18-22,28 Moreover, overall 
EXCITE study20 includes mostly patients from 
the Middle-East and Asia, which have limited 
data on antihypertensive treatment.
Postmarketing (PM) results from this real-
life setting reflect the real performance of the 
drug in daily clinical practice which is different 
from the highly restricted clinical trial setting. 
For medical practitioners, these PM results may 
be more applicable than the clinical trial results.
Another limitation is the subjective 
investigators’ assessment on the effectiveness, 
tolerability, compliance and adherence to 
treatment. Nonetheless, these results indicated 
the levels of patient adherence in daily clinical 
practice.
CONCLUSION
Aml/Val SPC was effective and well tolerated 
for BP reductions in patients with various grades 
and various types of essential hypertension, 
not controlled by prior monotherapy, in a daily 
clinical setting in Indonesia.
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